A new report demonstrates that female-dominated inventor teams in biomedical sciences are more likely to invent...
Sisters are doin’ it for themselves: female inventors more likely to invent for women
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Emily Bristow
Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management.
A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.
See Emily's full profile
Pearce IP BioBlast®: w/e 25 June 2021
23 Jun 21 | US | Genentech announced that the FDA has accepted the BLA for its Port Delivery System with ranibizumab...
Pearce IP BioBlast®: w/e 18 June 2021
10 June 21 | The UK's NICE published final draft guidance recommending adalimumab, etanercept and infliximab for the...
Pearce IP BioBlast®: w/e 11 June 2021
07 Jun 21 | Celltrion launched Remsima SC® (subcutaneous infliximab biosimilar) in Canada. Remsima SC® is indicated...
Australian Patent system review: an ineffectual hand-waving exercise?
A missed opportunity to introduce an alternative second-tier patent system!
Pearce IP recently reported on recommendations made by an independent review into the Australian patent system to...
Pearce IP BioBlast®: w/e 04 June 2021
31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald....
Pearce IP BioBlast®: w/e 28 May 2021
24 May 21 | IN | Zydus Cadila announced it has launched Ujvira (trastuzumab emtansine) in India. Ujvira is an antibody...
Pearce IP BioBlast®: w/e 21 May 2021
12 May 21 | Celltrion released its Q1 2020 financial results, reporting that YoY sales of Celltrion biosimilars...
Pearce IP BioBlast®: w/e 14 May 2021
11 May | US | Alvotech filed a federal lawsuit against AbbVie in the US District Court of the Eastern District of...
Unwrapping the (Patent) Box: much ado about nothing?
Australia's new 'Patent Box' tax break unlikely to incentivise medical and biotech R&D in Australia
On 11 May 2021, Treasurer Josh Frydenberg announced that the 2021-2022 Australian Federal Budget would introduce a...
To waive or not to waive: that is the question
Will IP waivers have any impact on COVID-19 vaccine rollouts?
IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support...
Pearce IP BioBlast®: w/e 07 May 2021
01 May 21 | Samsung Bioepis announced a new study demonstrating the structural, physicochemical and biological...
NSW & Victoria compete to establish AU’s first mRNA manufacturing facility
In light of the COVID-19 vaccine supply shortages in Australia, it was refreshing to hear NSW Premier Gladys...
Pearce IP BioBlast®: w/e 30 April 2021
23 April | Boehringer Ingelheim announced results from a Ph III switching study of Cyltezo® (biosimilar adalimumab)...
COVID-19 meltdown: why the rest of the world should be paying close attention to extreme drug shortages in India
As a second wave of COVID-19 ravages India, the rest of the world should be paying close attention to the reported...
Pearce IP BioBlast®: w/e 23 April 2021
15 April 21 | US | The Centre for Biosimilars reported a poster presented at AMCP 2021 shows a New York state Medicaid...